BioSpace News Archive

Largest dealer in the upper Midwest will serve Minnesota and North Dakota

New Tomosynthesis Biopsy software option received 510k clearance this month and is NOW available on the ASPIRE Cristalle digital mammography unit with DBT

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial.

The opioid overdose crisis continues to have a devastating effect on individuals, families and communities across the country, taking the life of a Canadian every two hours.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC) in Los Angeles.

Pharmazz, Inc., today announced that it has received permission to initiate a prospective, multicentric, randomized, double-blind, parallel, phase III clinical study to assess efficacy of PMZ-1620 along with standard treatment in patients of acute ischemic stroke in India.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, July 25, 2019, to discuss the company’s second quarter 2019 financial results

While a hot summer day might have you reaching for a fruit juice, the Minnesota Dental Association encourages parents and caregivers to be aware of sugar content in these thirst-quenching beverages and limit the amount given to children.

Diplomat Pharmacy, Inc. (NYSE: DPLO), will release its second-quarter 2019 operating results before market open Friday, August 9. A conference call and live webcast will be held at 8:30 a.m. ET.

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund.